• 5 min read
• Published on 10 October 2025
Listen to article
6:22Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
It wasn’t so long ago that we all got a rather rude awakening. The pandemic hit, and suddenly the journey of a simple pill from factory to pharmacy felt as precarious as a tightrope walk in a hurricane. It turns out that making everything on the other side of the world, while brilliant for the bottom line, is a bit of a nightmare when things go wrong. Now, it seems the penny has finally dropped for the pharmaceutical giants, and they’re scrambling to bring production back home.
When a company like AstraZeneca decides to splash out nearly £3.6 billion on a new factory in Virginia, you sit up and take notice. To me, this isn't just a new building. It's a colossal, expensive admission that the globalised supply chain model has some serious cracks. This single investment is a signal flare, illuminating a broader trend of ‘onshoring’. It tells the rest of the industry that relying on distant factories for essential medicines is no longer a viable strategy. And when one of the big fish makes a move this bold, you can be sure the others are watching, chequebooks at the ready.
Let’s be clear, building one of these facilities is nothing like putting up a new car plant or a warehouse. These are some of the most complex engineering projects imaginable. Think of it less as a factory and more as a hermetically sealed laboratory the size of a small town. You need specialist firms, the sort of engineering wizards who live and breathe regulatory compliance and cleanroom validation. Companies like Jacobs or Fluor have carved out a niche here, becoming the go-to experts for projects that would make most builders run for the hills. Their expertise is the secret sauce, and it creates a rather formidable barrier to entry for any would-be competitors.
Beyond the concrete and steel, there’s another revolution happening inside these new plants. The days of people in white coats meticulously counting pills are long gone. Modern pharmaceutical manufacturing is a ballet of advanced automation. Robots, sensors, and sophisticated software ensure every product is perfect, every single time. This means the companies providing this cutting-edge tech are riding two waves at once. They benefit from the initial construction boom, and then they benefit again from the long-term need for maintenance, upgrades, and optimisation. It’s a rather attractive position to be in, I think you’ll agree.
This whole movement isn’t just happening in a corporate vacuum. Politicians, smelling a chance to talk about national security and job creation, are throwing their weight behind it. Government incentives and policy changes are creating powerful tailwinds, making it financially and politically attractive for companies to build on home soil. When corporate strategy aligns so neatly with government policy, you tend to get a trend with real staying power. Of course, it's not all plain sailing. These grand projects are fraught with potential pitfalls, and a deeper look into the Pharma Onshoring Boom: Investment Risk Considerations is essential before getting too carried away. These are multi-year endeavours, which is great for sustained demand but also means a lot can go wrong along the way. Delays, cost overruns, and economic wobbles could all throw a spanner in the works. For investors, this is a long game, not a quick punt.
View the full Basket:Pharma Onshoring Boom: Investment Risk Considerations
View the full Basket:Pharma Onshoring Boom: Investment Risk Considerations
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article